• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬皮肤肥大细胞瘤中 KIT 蛋白表达和 c-kit 基因突变的预后和预测意义:肿瘤-病理学工作组的共识。

Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology-Pathology Working Group.

机构信息

Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado.

Dick White Referrals, Cambridge, UK.

出版信息

Vet Comp Oncol. 2019 Dec;17(4):451-455. doi: 10.1111/vco.12518. Epub 2019 Jul 9.

DOI:10.1111/vco.12518
PMID:31264352
Abstract

One of the primary objectives of the Oncology-Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic pathology. Consensus is established through critical review of peer-reviewed literature relevant to a subgroup's particular focus. Subsequent acceptance and approval of the document by the OPWG membership at large establishes consensus. The intent of this publication is to help educate practitioners and pathologists on the value of diagnostics related to the KIT receptor tyrosine kinase for canine cutaneous mast cell tumours and to provide a guide for the use of these tests in veterinary medicine. This document represents the opinions of the OPWG and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.

摘要

肿瘤病理学工作组(OPWG)是兽医癌症协会和美国兽医病理学家学院的联合倡议,其主要目标之一是让肿瘤学家和病理学家共同制定共识文件,以规范肿瘤病理学的各个方面并提供指导方针。通过对与特定小组重点相关的同行评议文献进行严格审查来达成共识。随后,OPWG 的全体成员接受和批准该文件即可确立共识。本出版物的目的是帮助从业者和病理学家了解与犬皮肤肥大细胞瘤的 KIT 受体酪氨酸激酶相关的诊断的价值,并为这些测试在兽医医学中的使用提供指南。本文件代表 OPWG 和作者的意见,并不构成美国兽医病理学家学院或兽医癌症协会的正式认可。

相似文献

1
Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology-Pathology Working Group.犬皮肤肥大细胞瘤中 KIT 蛋白表达和 c-kit 基因突变的预后和预测意义:肿瘤-病理学工作组的共识。
Vet Comp Oncol. 2019 Dec;17(4):451-455. doi: 10.1111/vco.12518. Epub 2019 Jul 9.
2
Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group.犬皮肤肥大细胞瘤分级的价值、局限性和建议:肿瘤-病理学工作组的共识。
Vet Pathol. 2021 Sep;58(5):858-863. doi: 10.1177/03009858211009785. Epub 2021 Apr 23.
3
The use, publication and future directions of immunocytochemistry in veterinary medicine: a consensus of the Oncology-Pathology Working Group.免疫细胞化学在兽医学中的应用、发表情况及未来方向:肿瘤病理学工作组的共识
Vet Comp Oncol. 2017 Sep;15(3):868-880. doi: 10.1111/vco.12228. Epub 2016 Mar 22.
4
Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: A consensus of the Oncology-Pathology Working Group.犬黑色素瘤肿瘤的诊断和组织病理学预后:肿瘤病理学工作组的共识。
Vet Comp Oncol. 2022 Dec;20(4):739-751. doi: 10.1111/vco.12827. Epub 2022 Jul 4.
5
Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.澳大利亚犬肥大细胞瘤中C-KIT原癌基因第11外显子内部串联重复的患病率。
Aust Vet J. 2017 Oct;95(10):386-391. doi: 10.1111/avj.12636.
6
Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.验证组织病理学分级或 c-kit 突变在犬皮肤肥大细胞瘤预后中的价值:一项回顾性队列研究。
Vet J. 2013 Jun;196(3):492-8. doi: 10.1016/j.tvjl.2012.11.018. Epub 2013 Feb 4.
7
In situ c-KIT mRNA quantification of canine cutaneous mast cell tumours and its relationship to prognostic factors.犬皮肤肥大细胞瘤原位 c-KIT mRNA 定量及其与预后因素的关系。
Vet Comp Oncol. 2021 Mar;19(1):132-139. doi: 10.1111/vco.12650. Epub 2020 Nov 3.
8
The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.使用实时聚合酶链反应和免疫组织化学分析KIT和KIT配体的分子表达作为犬皮肤肥大细胞瘤预后指标的价值。
Vet Comp Oncol. 2015 Mar;13(1):1-10. doi: 10.1111/vco.12010. Epub 2013 Jan 7.
9
HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors.犬皮肤肥大细胞瘤中HSP32和HSP90免疫表达与Kit模式、分级及有丝分裂计数的关系
Vet Pathol. 2017 Mar;54(2):222-225. doi: 10.1177/0300985816669405. Epub 2016 Sep 29.
10
Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.犬皮下肥大细胞瘤:细胞增殖和 KIT 表达作为预后指标。
Vet Pathol. 2011 Jan;48(1):169-81. doi: 10.1177/0300985810390716. Epub 2010 Dec 15.

引用本文的文献

1
PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer.聚(ADP-核糖)聚合酶(PARP)抑制剂奥拉帕利可诱导DNA损伤,并在犬类造血癌的体外模型中作为一种药物增敏剂发挥作用。
BMC Vet Res. 2025 Jul 5;21(1):439. doi: 10.1186/s12917-025-04880-z.
2
Expression Profile of Twelve Transcripts as a Supporting Tool for the Molecular Characterization of Canine Cutaneous Mast Cell Tumors at Diagnosis: Association with Histological Grading and Clinical Staging.十二种转录本的表达谱作为犬皮肤肥大细胞瘤诊断时分子特征分析的辅助工具:与组织学分级和临床分期的关联
Genes (Basel). 2025 Mar 14;16(3):340. doi: 10.3390/genes16030340.
3
Mutational Landscape of Proto-Oncogene Coding Sequence in 62 Canine Cutaneous and Subcutaneous Mast Cell Tumors.
62例犬皮肤和皮下肥大细胞瘤中原癌基因编码序列的突变图谱
Vet Sci. 2024 Nov 25;11(12):593. doi: 10.3390/vetsci11120593.
4
Artificial intelligence can be trained to predict -11 mutational status of canine mast cell tumors from hematoxylin and eosin-stained histological slides.人工智能可以通过苏木精和伊红染色的组织学切片来训练预测犬肥大细胞瘤的-11突变状态。
Vet Pathol. 2025 Mar;62(2):152-160. doi: 10.1177/03009858241286806. Epub 2024 Oct 18.
5
Novel genomic prognostic biomarkers for dogs with cancer.具有癌症的犬的新型基因组预后生物标志物。
J Vet Intern Med. 2023 Nov-Dec;37(6):2410-2421. doi: 10.1111/jvim.16893. Epub 2023 Oct 6.
6
Evaluating the Histologic Grade of Digital Squamous Cell Carcinomas in Dogs and Copy Number Variation of KIT Ligand-A Correlation Study.犬指部鳞状细胞癌组织学分级及KIT配体拷贝数变异的相关性研究
Vet Sci. 2023 Jan 24;10(2):88. doi: 10.3390/vetsci10020088.
7
Preliminary Assessment of Tumor-Associated Tissue Eosinophilia (TATE) in Canine Mast Cell Tumors: Prevalence and Prognostic Relevance and Its Association with Neoangiogenesis.犬肥大细胞瘤中肿瘤相关组织嗜酸性粒细胞增多症(TATE)的初步评估:患病率、预后相关性及其与新生血管形成的关联
Animals (Basel). 2023 Jan 13;13(2):283. doi: 10.3390/ani13020283.
8
Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.使用肿瘤内注射替吉兰醇替格列酯治疗犬多发性同步肥大细胞瘤。
Front Vet Sci. 2022 Oct 26;9:1003165. doi: 10.3389/fvets.2022.1003165. eCollection 2022.
9
Canine mast cell tumours part I: Clinical and survival outcomes.犬肥大细胞瘤第一部分:临床和生存结果。
Vet Med Sci. 2022 Jul;8(4):1409-1420. doi: 10.1002/vms3.812. Epub 2022 May 3.
10
Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.犬肥大细胞瘤的拟议诊断标准与分类:一项共识提议
Front Vet Sci. 2021 Dec 10;8:755258. doi: 10.3389/fvets.2021.755258. eCollection 2021.